Ggt enzyme-responsive dexamethasone-oligopeptide antifibrotic prodrugs, preparations and uses
By designing a GGT enzyme-responsive dexamethasone-oligopeptide prodrug, the targeting and side effects of dexamethasone in the treatment of liver fibrosis were solved, achieving precise delivery to the site of liver fibrosis and dual therapeutic effects, significantly inhibiting the fibrosis process.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- XINGHUOZHIYAO (BEIJING) TECH CO LTD
- Filing Date
- 2026-05-29
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies for the treatment of liver fibrosis with dexamethasone have problems with systemic side effects and poor targeting, making it difficult to achieve precise targeted delivery and specific release. Furthermore, traditional nanocarriers cannot effectively solve the problems of off-target toxicity and inaccurate drug release.
We designed and synthesized a GGT enzyme-responsive dexamethasone-oligopeptide prodrug for liver fibrosis. By covalently coupling dexamethasone and oligopeptide through Michael addition reaction, we formed self-assembled nanoparticles, which enabled precise self-release of the drug at the site of liver fibrosis lesions and combined anti-inflammatory and immunomodulatory effects.
It achieves precise delivery and specific release of drugs at the site of liver fibrosis, significantly reduces systemic side effects, inhibits the progression of liver fibrosis, and demonstrates more comprehensive therapeutic potential than traditional drugs.
Smart Images
Figure CN122404486A_ABST